Methods of Inhibiting Poxvirus Growth

A method of inhibiting poxvirus growth comprising contacting the poxvirus with a growth inhibitory amount of at least one compound having the formula:

• wherein R1-4 are independently hydrogen, aliphatic, sulfonyl, alkoxy, nitro, phosphonate, or carbonyl-containing;
• R5, R6, R7 and R8 are independently hydrogen or aliphatic;
• X1-X12 are independently hydrogen or halogen;
• and bonds between C1-C2 and C3-C4 are independently a single bond or a double bond;
• wherein Y1 and Y2 are independently O, S, or N—R (wherein R is hydrogen or aliphatic);
• R1 is hydroxyl, alkoxy, amino, or azo;
• R2 is hydrogen, aliphatic, or sulfonyl;
• R3 is hydrogen, aliphatic, or carbonyl-containing;
• R4 is hydrogen, aliphatic, or amino;
• R5, R6 and R7 are independently hydrogen, hydroxyl, alkoxy, carbonyl-containing, sulfonyl, or phosphonate;
• and R8 is hydrogen or aliphatic;
• wherein R1 is aliphatic substituted with one or more carbonyl-containing and/or sulfonyl groups;
• and R2-R4 are independently hydrogen or aliphatic;
• wherein (R1)n represents four substituents independently selected from hydrogen, aliphatic, or aryl;
• R2, R4, and R5 are independently hydrogen, aliphatic, sulfonyl, hydroxyl, alkoxy, nitro, phosphonate, or carbonyl-containing;
• R3 is hydrogen or aliphatic;
• and R6 is hydrogen or amino;
• wherein X is sulfonyl, phosphonate, carbonyl-containing, or —Sb(O)(OH)2 (or its conjugate base);
• and R1, R2 and R3 are independently hydrogen or aliphatic;
• or
• wherein R1, R2, and R4-R7 are independently hydrogen or aliphatic;
• and (R3)n represents five substituents independently selected from hydrogen, aliphatic, carbonyl-containing, sulfonyl, phosphonate, hydroxyl, and alkoxy.

A method for treating poxvirus infection in a subject, comprising administering to a subject a therapeutically effective amount of at least one compound having the formula:

• wherein R1-4 are independently hydrogen, aliphatic, sulfonyl, alkoxy, nitro, phosphonate, or carbonyl-containing;
• R5, R6, R7 and R8 are independently hydrogen or aliphatic;
• X1-X12 are independently hydrogen or halogen;
• and bonds between C1-C2 and C3-C4 are independently a single bond or a double bond;
• wherein Y1 and Y2 are independently O, S, or N—R (wherein R is hydrogen or aliphatic);
• R1 is hydroxyl, alkoxy, amino, or azo;
• R2 is hydrogen, aliphatic, or sulfonyl;
• R3 is hydrogen, aliphatic, or carbonyl-containing;
• R4 is hydrogen, aliphatic, or amino;
• R5, R6 and R7 are independently hydrogen, hydroxyl, alkoxy, carbonyl-containing, sulfonyl, or phosphonate;
• and R8 is hydrogen or aliphatic;
• wherein R1 is aliphatic substituted with one or more carbonyl-containing and/or sulfonyl groups;
• and R2-R4 are independently hydrogen or aliphatic;
• wherein (R1)n represents four substituents independently selected from hydrogen, aliphatic, or aryl;
• R2, R4, and R5 are independently hydrogen, aliphatic, sulfonyl, hydroxyl, alkoxy, nitro, phosphonate, or carbonyl-containing;
• R3 is hydrogen or aliphatic;
• and R6 is hydrogen or amino;
• wherein X is sulfonyl, phosphonate, carbonyl-containing, or —Sb(O)(OH)2 (or its conjugate base);
• and R1, R2 and R3 are independently hydrogen or aliphatic;
• or
• wherein R1, R2, and R4-R7 are independently hydrogen or aliphatic;
• and (R3)n represents five substituents independently selected from hydrogen, aliphatic, carbonyl-containing, sulfonyl, phosphonate, hydroxyl, and alkoxy;
• and
• wherein administering the at least one compound treats poxvirus infection in the subject.

The method of 23, wherein the at least one compound has the structure:

• wherein R2 is hydrogen, aliphatic, or sulfonyl;
• R4 is hydrogen, aliphatic, or amino;
• R15 is hydrogen or lower alkyl;
• and R16 is aryl;
• or
• wherein R2 and R9-R14 are independently hydrogen or aliphatic.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound having the formula:

• wherein R1-4 are independently hydrogen, aliphatic, sulfonyl, alkoxy, nitro, phosphonate, or carbonyl-containing;
• R5, R6, R7 and R8 are independently hydrogen or aliphatic;
• X1-X12 are independently hydrogen or halogen;
• and bonds between C1-C2 and C3-C4 are independently a single bond or a double bond;
• wherein Y1 and Y2 are independently O, S, or N—R (wherein R is hydrogen or aliphatic);
• R1 is hydroxyl, alkoxy, amino, or azo;
• R2 is hydrogen, aliphatic, or sulfonyl;
• R3 is hydrogen, aliphatic, or carbonyl-containing;
• R4 is hydrogen, aliphatic, or amino;
• R5, R6 and R7 are independently hydrogen, hydroxyl, alkoxy, carbonyl-containing, sulfonyl, or phosphonate;
• and R8 is hydrogen or aliphatic;
• wherein R1 is aliphatic substituted with one or more carbonyl-containing and/or sulfonyl groups;
• and R2-R4 are independently hydrogen or aliphatic;
• wherein (R1)n represents four substituents independently selected from hydrogen, aliphatic, or aryl;
• R2, R4, and R5 are independently hydrogen, aliphatic, sulfonyl, hydroxyl, alkoxy, nitro, phosphonate, or carbonyl-containing;
• R3 is hydrogen or aliphatic;
• and R6 is hydrogen or amino;
• wherein X is sulfonyl, phosphonate, carbonyl-containing, or —Sb(O)(OH)2 (or its conjugate base);
• and R1, R2 and R3 are independently hydrogen or aliphatic;
• or
• wherein R1, R2, and R4-R7 are independently hydrogen or aliphatic;
• and (R3)n represents five substituents independently selected from hydrogen, aliphatic, carbonyl-containing, sulfonyl, phosphonate, hydroxyl, and alkoxy.